Drug updated on 9/4/2024
Dosage Form | Tablet (oral; 50 mg) |
Drug Class | Sodium/hydrogen exchanger 3 (NHE3) inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
Latest News
Summary
- Ibsrela (tenapanor) is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
- This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
- Tenapanor significantly reduced serum phosphorus levels in hemodialysis patients with hyperphosphatemia by a mean difference of 1.79 mg/dl compared to placebo.
- Tenapanor was superior to placebo for improving abdominal bloating in IBS-C patients, but indirect comparisons revealed no significant differences in efficacy when compared to other drugs like Linaclotide, Lubiprostone, and Tegaserod.
- Specific comparative efficacy data for Tenapanor in treating chronic idiopathic constipation were not detailed, though it was included in the network meta-analysis.
- Diarrhea, gastrointestinal adverse events (AEs), and drug-related AEs were more severe in patients treated with tenapanor compared to placebo.
- The safety profile of tenapanor was not specifically detailed in two of the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Ibsrela (tenapanor) Prescribing Information. | 2022 | Ardelyx Inc., Waltham, MA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of randomized placebo-controlled trials | 2023 | Therapeutic Apheresis and Dialysis |
Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. | 2021 | Alimentary Pharmacology and Therapeutics |
Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. | 2019 | The Lancet Gastroenterology & Hepatology |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. | 2022 | Gastroenterology |